While the co-targeting of BCLxL and/or MCL1 may well be challenging because of on-target toxicities9, the action of the BH3 mimetics could be restricted to tumor cells with antibody–drug conjugates to preferentially target tumor tissues. This evidence concerns the gene MCL1 and neoplasm.